Explore the Agenda
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Understanding Success Stories to Spearhead the Future of RNAi Therapeutics
9:00 am Fireside Chat: Learning Lessons from Clinical-Stage RNAi Programs to Improve Study Progression from Preclinical Phases
- Learn from companies advancing through late-stage development
- Identify recurring challenges and successful solutions
- Apply practical insights to accelerate program progression
10:00 am Pioneering Advancements to Push Boundaries in Patient Care
- Explore the technologies emerging after the first wave of RNAi success
- Assess opportunities to further improve potency and durability
- Extend the commercial and clinical impact of tissue selective RNAi therapeutics
10:30 am Morning Break & Networking
Understanding Key Factors to Develop Strong Investment & Funding Partnerships
11:00 am Panel Discussion: Securing Funding and Strategic Partnerships to Accelerate RNAi Innovation
- Understand what investors and pharmaceutical partners look for
- Learn how to find and build relationships with investors/partners interested in your field
- Gain insights into the key conferences, partnering forums and networking platforms that are shaping investment and dealmaking
12:00 pm Lunch Break & Networking
Driving RNAi Beyond Established Indications to Address Unmet Patient Needs
1:00 pm Developing Tetravalent siRNAs for Efficient and Safe Silencing of Retinal Genes
- Exploring chemistries for retinal genes silencing
- Understanding target cells for disease alterations
- Establishing pre-clinical efficacies and safety in non-human primates
New Data
1:30 pm Panel Discussion: Balancing Potency, Specificity & Therapeutic Index to Ensure Safe RNAi Therapies
- Understanding the drivers of RNAi-related toxicity
- Optimizing delivery, chemistry & dosing to improve therapeutic index
- Building confidence in safety as RNAi expands beyond the liver
2:30 pm Afternoon Break & Networking
Driving RNAi Beyond Established Indications to Address Unmet Patient Needs
3:00 pm Establishing Multi-Target RNAi Strategies for Complex Tumour Biology
- Exploring dual and multi-gene silencing approaches designed to overcome pathway redundancy
- Addressing tumour adaptation and resistance mechanisms through combinatorial targeting
- Improving treatment responses across heterogeneous cancer populations
3:30 pm Targeting Megalin for Delivery of Genetic Medicines to the Kidney
- Employing Megalin-mediated selective delivery of oligonucleotides to kidney proximal tubule epithelial cells
- Developing potent, durable, kidney-specific gene silencing with cell-type precision
- Exploring emerging applications for kidney and systemic diseases.